TCIM
TTNP

TIAA CREF Investment Management’s Titan Pharmaceuticals TTNP Stock Holding History

TIAA CREF Investment Management’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-15
Closed -$180K – 3177
2017
Q1 		$180K Sell
15
-1
-6% -$14.1K ﹤0.01% 3007
2016
Q4 		$225K Sell
16
-2
-11% -$33.7K ﹤0.01% 3028
2016
Q3 		$372 Hold
18
– – ﹤0.01% 2952
2016
Q2 		$346K Buy
+18
New +$383K ﹤0.01% 2999

Other funds holding TTNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MERSOM
Municipal Employees' Retirement System of Michigan Lansing, Michigan $8.81B AUM 10.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WPA
Winning Points Advisors Boca Raton, Florida $74.8M AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

TIAA CREF Investment Management's TTNP Position: Q2 2017 in Review

TIAA CREF Investment Management sold out of Titan Pharmaceuticals (TTNP) in Q2 2017, closing a stake of 15 shares — an estimated $180K sold.

TIAA CREF Investment Management first reported a position in TTNP in Q2 2016 and held it in 4 quarters. The position peaked at $346K in Q2 2016. 35 funds tracked by Wall St. Rank hold TTNP as of Q2 2017.

  • TIAA CREF Investment Management reported no remaining Titan Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • TIAA CREF Investment Management sold 15 Titan Pharmaceuticals shares in Q2 2017, an estimated $180K.
  • TIAA CREF Investment Management first reported a position in Titan Pharmaceuticals in Q2 2016 and held it in 4 quarters.
  • TIAA CREF Investment Management's Titan Pharmaceuticals position peaked at $346K in Q2 2016.
  • 35 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q2 2017.

Based on TIAA CREF Investment Management's 13F filing for Q2 2017, filed 10 Aug 2017.